There are Mondays that feel routine and then there are Mondays that quietly rearrange the map. This one started with the usual early weakness across the major averages, yet beneath the surface two very different stories were unfolding at once. Memory-chip names and optical-component suppliers kept charging higher, extending last week’s powerful run, while a large slice of the software complex was handing back the gains it had just collected. Somewhere in the middle of that tug-of-war the weekly prescription numbers landed and suddenly the pharmaceutical side of the market looked a lot more interesting than most people had expected when they opened their screens.
A Split Session Sets The Tone For The Week
The broader tape opened lower and stayed under modest pressure through the afternoon. That alone would not have been surprising after a strong stretch in technology. What caught attention was the clear divergence inside the growth universe. On one side the so-called AI hardware trade continued to attract buyers. Memory names such as Micron and Sandisk pushed higher again. Optical and networking suppliers including Corning, Marvell Technology and Coherent also advanced, riding the same wave of optimism about data-center build-outs and high-bandwidth demand.
On the other side sat the software group, and the mood there was noticeably different. Last Thursday a report that private-equity firm Silver Lake had held talks with Workday sent the enterprise-software name soaring on its best day in nearly a decade. Shorts scrambled to cover and several peers, Salesforce among them, caught a sympathetic bid. By Monday morning that enthusiasm had cooled. With no fresh confirmation of a deal, the shares drifted lower and dragged several other software names with them. CrowdStrike and Palo Alto Networks felt the pressure even though both companies have repeatedly told investors that artificial-intelligence tools are expanding rather than threatening their core businesses.
I’ve watched this pattern play out more than once. A takeover rumor lights a fire under a group, the short covering creates a sharp spike, and then the absence of follow-through lets the air out again. It does not mean the underlying companies are broken. It simply means the market is quick to reprice when the catalyst remains only a rumor.
Rates Keep Creeping Higher Ahead Of Key Fed Events
While the equity tape was sorting itself into winners and losers, the bond market continued its own quiet move. The ten-year yield pushed above 4.7 percent, extending a multi-session climb. That advance arrives at an awkward moment on the calendar. Wednesday brings the release of the minutes from the July Federal Open Market Committee meeting. Those pages often contain more nuance than the post-meeting statement itself. A week later many of the world’s central bankers will gather at Jackson Hole. Markets tend to listen carefully to every syllable spoken in that mountain setting.
Higher yields rarely help growth stocks, and the software complex is especially sensitive. When the risk-free rate rises, the present value of distant cash flows shrinks and valuation multiples come under pressure. That dynamic helps explain why the same names that rallied on takeover chatter were quick to give ground once the yield curve started moving again.
Eli Lilly’s Oral Pill Finally Starts To Close The Gap
Against that backdrop the two pharmaceutical holdings in the portfolio stood out for the right reasons. Weekly prescription data compiled from IQVIA figures showed Eli Lilly’s oral GLP-1 medicine, Foundayo, continuing to gain traction. For the week ending August 7 the total prescriptions for the competing oral version of Wegovy still led at roughly 163,000, yet that number declined about five percent from the prior week. Foundayo, by contrast, rose fourteen percent to approximately 38,900 prescriptions.
The absolute numbers remain far apart, of course. What matters is the direction and the timing. On its most recent earnings call Lilly management had indicated that broader consumer marketing was only beginning to ramp. Awareness, they said, was still in the early innings. The latest weekly data appear to line up almost perfectly with that guidance. The pill that once looked as if it might lag is now posting consistent sequential gains.
I’ve long preferred Foundayo for patients who need long-term weight-loss maintenance rather than a short intensive phase. The absence of strict time-of-day or food-and-water restrictions makes daily life simpler. That practical edge may not show up in the first few weeks of launch data, but it tends to matter once people settle into a routine. The current numbers suggest that message is starting to reach more patients and physicians.
While the competing pill got off to a faster start and offers slightly greater average weight loss in trial data, the convenience profile of Foundayo has always looked better suited to the maintenance phase that most patients eventually need.
None of this means the race is over. Novo Nordisk still holds a clear lead in absolute prescriptions and possesses deep experience in the category. Yet the sequential improvement at Lilly is the first solid evidence that the marketing investment is translating into real-world demand. For investors who own the stock, that shift is worth watching closely in the weeks ahead.
Johnson & Johnson’s Newest Oral Option Begins To Accelerate
A second piece of the same weekly report focused on Johnson & Johnson’s oral IL-23 inhibitor Icotyde, approved for moderate-to-severe plaque psoriasis. Like the oral obesity medicines, Icotyde is designed to capture share from injectable alternatives. Early prescription trends had been modest. The latest data, however, show a clear acceleration as additional payers expand coverage.
Among the company’s recent launches this is the product that looks most capable of becoming a genuine blockbuster. Dermatology is a competitive field, yet the convenience of a daily pill versus injections remains a powerful differentiator for many patients. Once coverage improves, the prescription curve often steepens quickly. That appears to be the stage Icotyde has now entered.
The broader psoriasis market has already proven that oral options can take meaningful share when efficacy is competitive and side-effect profiles are manageable. Icotyde sits in that sweet spot. Continued gains in weekly prescriptions would reinforce the view that this particular asset deserves a higher valuation multiple inside the overall Johnson & Johnson portfolio.
What The Data Mean For The Rest Of The Portfolio
Both names are already held in the charitable trust, so the fresh numbers do not trigger an immediate portfolio change. They do, however, strengthen the fundamental case. In a market that has grown increasingly selective, companies showing tangible evidence of product-cycle success tend to hold up better when broader sentiment turns cautious. The contrast with the software group is instructive. There the narrative remains largely about future potential and possible corporate actions. In the pharmaceutical space the narrative is starting to be backed by actual prescription counts that move week to week.
That difference matters. Markets ultimately reward cash-flow growth more than they reward stories. When the prescription data confirm the story, the valuation conversation becomes easier.
Retail Earnings Arrive Into A High-Rate Backdrop
Looking ahead, the calendar turns quickly to retail. Home Depot reports before the open on Tuesday, the first of several large names scheduled this week. Expectations for growth remain muted. Persistently elevated interest rates have slowed housing turnover, and that directly affects demand for big-ticket home-improvement projects. Management will almost certainly face questions about the health of the professional customer and about the integration of the specialty building-products acquisition that brought GMS into the larger SRS Distribution platform.
Wednesday brings results from TJX Companies, parent of the TJ Maxx banner, along with Target and Lowe’s. Walmart follows on Thursday. Collectively these reports will give the market a clearer picture of how the American consumer is navigating higher borrowing costs and still-elevated prices in certain categories. The professional and do-it-yourself channels have diverged at times in recent quarters; any commentary that narrows or widens that gap will move the stocks.
I’ve found that retail management teams are usually candid about the rate environment. They live with it every day. When they begin to sound more constructive, the market tends to listen. Until that tone shifts, the group is likely to remain range-bound even on solid execution.
AI Hardware Momentum Versus Hyperscaler Spending Concerns
The continued strength in memory and optical names sits in deliberate contrast to the softer tone among the large cloud providers. The market has begun to separate the companies that supply the physical infrastructure from those that write the checks. Higher capital expenditure is good for the suppliers and, at least in the short run, a margin headwind for the hyperscalers. That tension is unlikely to resolve overnight. As long as data-center demand remains robust, the component makers should continue to enjoy a favorable demand environment even if the stock prices of their largest customers lag.
Corning’s optical fiber and specialty glass, Marvell’s high-speed interconnect silicon, and Coherent’s laser and networking components all sit in the middle of that build-out. Their recent price action suggests investors are willing to pay for visible volume growth rather than waiting for the next earnings print from the cloud giants.
Software Valuation And The Takeover Premium Question
The fade in software shares raises a longer-term question. Many of these companies still trade at elevated multiples relative to historical averages. When a private-equity rumor surfaces, the market briefly prices in a takeout premium. When the rumor goes quiet, that premium evaporates and the residual valuation can look stretched again. CrowdStrike and Palo Alto Networks both have strong competitive positions and management teams that speak confidently about artificial intelligence as an accelerant rather than a threat. Yet the group as a whole remains sensitive to any shift in risk appetite or interest-rate expectations.
Perhaps the most interesting aspect is how quickly sentiment can reverse. Last week the narrative was about private capital validating high software valuations. This week the narrative is about the absence of confirmed deals and the presence of higher yields. Both narratives can be true at different moments. The practical implication for portfolio construction is simple: size positions so that a sudden change in the story does not force an emotional decision.
Putting The Pieces Together For The Days Ahead
Monday’s session offered a useful reminder that markets rarely move in a single direction. Hardware tied to artificial-intelligence infrastructure kept climbing. Software that had briefly enjoyed a takeover bounce gave ground. Yields rose. And two pharmaceutical names posted encouraging weekly prescription trends that aligned with management commentary delivered only weeks earlier.
The next few sessions will layer additional information on top of that foundation. Fed minutes on Wednesday, retail earnings throughout the week, and the approach of Jackson Hole will all influence the tone. Inside the portfolio the focus remains on companies that can demonstrate real product progress rather than those whose stories depend primarily on potential corporate activity.
Foundayo’s sequential gains and Icotyde’s accelerating prescriptions are small data points on their own. Taken together they reinforce a larger idea: when a company invests in a differentiated product and then supports it with marketing and payer access, the prescription curve eventually bends upward. Watching that curve week by week remains one of the more reliable ways to stay ahead of the next valuation debate.
For now the market is still sorting winners from laggards. The names showing tangible evidence of demand growth are the ones that look best positioned to weather whatever the rate and sentiment environment delivers next. That is the practical takeaway from a Monday that began with broad weakness and ended with a clearer distinction between stories and substance.
A Closer Look At The Prescription Dynamics
Weekly prescription data are noisy by nature. A single week can be distorted by holidays, inventory adjustments or temporary access issues. That is why sequential trends over several weeks matter more than any isolated print. Foundayo’s fourteen-percent rise after earlier periods of slower growth is the first clear sign that the awareness campaign is landing. The absolute gap with the leading oral competitor remains large, yet the direction of travel has shifted. In past product launches that shift has often preceded more material share gains once physicians become comfortable writing the new prescription and patients report real-world experiences.
The same logic applies to Icotyde. Dermatology prescriptions tend to build more gradually than metabolic drugs because the patient population is smaller and the switching decision is less urgent. Once payer coverage expands, however, the barrier falls and the weekly numbers can accelerate quickly. The latest report suggests that inflection is underway. If the trend continues, the product will begin to contribute more meaningfully to Johnson & Johnson’s growth algorithm than many models currently assume.
Both situations illustrate a broader point about pharmaceutical investing. Early launch curves often disappoint relative to peak expectations. The companies that succeed are those that stay patient, invest behind the brand, and let the convenience and efficacy advantages compound over time. The current data for both Foundayo and Icotyde are consistent with that pattern.
Interest Rates And The Valuation Reset Risk
The climb in the ten-year yield above 4.7 percent is not dramatic in isolation, yet it arrives after a period when many growth stocks had already rerated higher on the assumption that rates had peaked. Every additional basis point raises the discount rate applied to future cash flows. Software companies with high multiples and cash flows that arrive years from now feel that pressure first. Pharmaceutical companies with nearer-term product cycles and more defensive demand characteristics tend to hold up better.
That relative resilience is visible in Monday’s price action. While software names retreated, the two pharma holdings advanced on the back of concrete prescription data. The divergence is unlikely to reverse simply because yields stabilize. It will reverse only when either the software group delivers better-than-expected growth or the prescription momentum at Lilly and Johnson & Johnson stalls. At the moment the evidence favors the latter group.
Retail’s Rate Sensitivity Remains The Central Question
Home Depot’s report will set the tone for the rest of the retail calendar. Management has already guided for limited growth given the housing market’s sensitivity to mortgage rates. The more interesting questions concern the professional customer and the integration progress of the recent specialty acquisition. If the Pro segment continues to outperform the do-it-yourself channel, that would suggest commercial construction and renovation activity is holding up better than residential. Such a split has appeared in prior rate cycles and can persist longer than many expect.
TJX Companies operates in a different part of the retail spectrum. Off-price apparel and home goods have historically shown resilience when consumers trade down. Target sits closer to the middle of the income spectrum and has faced more pressure on discretionary categories. Lowe’s and Walmart complete the picture with their respective exposures to home improvement and everyday consumables. Together the four reports will give a reasonably complete snapshot of consumer health under the current rate regime.
None of these companies is expected to post robust top-line acceleration. The market will focus instead on margin commentary, inventory discipline and any forward-looking language about the second half of the year. In a high-rate environment, steady execution and careful cost control often matter more than growth for its own sake.
The Hardware Versus Software Divide Inside Technology
The strength in memory and optical names is not a short-term trading phenomenon. It reflects a multi-year build-out of data-center capacity that requires more high-bandwidth optical interconnects, more advanced memory, and more specialized silicon. The suppliers of those components are seeing order books that stretch well into next year. The hyperscalers that ultimately buy the finished servers and networking gear are simultaneously absorbing higher capital expenditures that pressure near-term margins. That tension creates the visible split in stock performance.
Investors who prefer to stay closer to the physical infrastructure have been rewarded in recent sessions. Those who prefer the software layer have faced more volatility, especially when takeover rumors fade and yields rise. Both approaches can work over a full cycle. The key is recognizing which part of the cycle currently dominates price action.
Monday offered a clear illustration. The hardware side kept climbing. The software side gave back earlier gains. The prescription data from the pharmaceutical holdings provided an independent source of positive fundamental news that stood apart from the technology debate altogether.
Practical Implications For Position Sizing And Patience
In an environment where narratives can shift within days, position sizing becomes more important than ever. A modest allocation to a name with accelerating prescriptions can be held through short-term market noise. A large allocation to a name whose recent strength rested primarily on an unconfirmed takeover rumor can force uncomfortable decisions when the rumor cools. The charitable trust approach of waiting for clear evidence before adding, and of keeping individual weights disciplined, is designed for exactly these conditions.
Foundayo and Icotyde are still early in their commercial lives. The weekly numbers will fluctuate. What matters is the multi-week trend and the qualitative feedback from physicians and patients. So far both point in a constructive direction. That is enough to maintain confidence without requiring aggressive additional buying on any single data point.
The same discipline applies to the software holdings that may have been lifted by last week’s rumor. Ownership remains justified by the underlying competitive positions and the long-term opportunity created by artificial intelligence. Ownership is not justified by the temporary presence of a private-equity rumor. Distinguishing between those two reasons is the difference between patient capital and speculative capital.
Looking Beyond The Immediate Catalysts
Jackson Hole and the Fed minutes will dominate headlines in the coming days. Retail earnings will fill the gaps between those events. Yet the more durable story may be the one unfolding in the weekly prescription reports. Two products that were expected to gain share are now showing early evidence that the share gains are materializing. In a market that has become highly selective, that kind of tangible progress tends to be rewarded over time.
The software complex will eventually find its next catalyst, whether through confirmed deals, better-than-expected earnings or a stabilization in yields. Until then the group is likely to remain range-bound and sensitive to every shift in risk appetite. The pharmaceutical names, by contrast, have a clearer fundamental path if the prescription trends continue.
That is the real message from Monday’s session. Markets can be noisy and contradictory in the short run. Beneath the noise, companies that deliver sequential improvement in real-world demand still attract capital. Eli Lilly and Johnson & Johnson both provided that evidence this week. The rest of the tape is still sorting itself out.
For investors willing to look past the daily scoreboard, the distinction between stories and substance remains the most reliable guide. The prescription data supplied a small but useful dose of substance. In a market that has grown accustomed to narrative-driven moves, that dose is worth paying attention to.
